VolitionRx Limited's Financial Performance Analysis

• VolitionRx Limited (AMEX:VNRX) CEO's significant stock purchase signals strong insider confidence.
• The company's groundbreaking research in veterinary cancer screening opens up new market opportunities.
• Despite pioneering advancements, VolitionRx faces financial hurdles with high valuation metrics and liquidity concerns.

VolitionRx Limited, listed on the NYSE American as AMEX:VNRX, is a multi-national epigenetics company. It focuses on developing blood tests to diagnose a range of diseases, including cancer. The company recently made headlines when its director, President, and CEO, Reynolds Cameron John, purchased 20,000 shares at $0.44 each, increasing his total holdings to 2,319,222 shares.

VolitionRx has achieved a significant milestone in veterinary research. The company published a clinical paper on detecting nucleosomes in cats, a first in the field. This breakthrough could lead to new cancer screening methods for felines, tapping into a market of over 60 million cats in the U.S., 25% of which are senior and suitable for annual checks.

Despite these advancements, VNRX faces financial challenges. The company has a high price-to-sales ratio of 32.38, indicating that investors are paying over 32 times its sales. The enterprise value to sales ratio is similar at 31.79, reflecting a high valuation despite negative earnings and a negative earnings yield of -60.52%.

The company's financial instability is further highlighted by a negative price-to-earnings ratio of -1.65 and a negative enterprise value to operating cash flow ratio of -1.90. These figures suggest difficulties in generating positive cash flow and profitability. Additionally, the debt-to-equity ratio of -0.09 indicates more equity than debt, but the negative value raises concerns about financial stability.

Liquidity is another concern for VolitionRx, with a current ratio of 0.40. This suggests the company may struggle to cover its current liabilities with its current assets. Despite these financial hurdles, the recent scientific breakthrough in veterinary research presents a promising commercial opportunity for the company.

• VolitionRx Limited (NYSEAMERICAN:VNRX) reported an EPS of -$0.06, aligning with estimates and generating revenue of approximately $593,000, surpassing expectations.
• The company's financial metrics reveal challenges, including a negative P/E ratio of -1.62 and a high price-to-sales ratio of 41.05, indicating market expectations of future growth despite current financial difficulties.
• VNRX faces liquidity challenges with a current ratio of 0.22 and negative operating cash flow, as indicated by an enterprise value to operating cash flow ratio of -3.84.

VolitionRx Limited, trading as NYSEAMERICAN:VNRX, is a company focused on developing blood tests for cancer detection. On March 31, 2025, VNRX reported an earnings per share (EPS) of -$0.06, aligning with the estimated EPS of -$0.06. The company generated a revenue of approximately $593,000, surpassing the estimated revenue of about $545,000.

Despite matching EPS estimates, VNRX's financial metrics reveal challenges. The company has a negative price-to-earnings (P/E) ratio of -1.62, indicating negative earnings. This suggests that the company is not currently profitable, which can be a concern for investors looking for growth.

The price-to-sales ratio of 41.05 indicates that investors are paying $41.05 for every dollar of sales generated by VNRX. This high ratio suggests that the market has high expectations for the company's future growth, despite its current financial challenges. Similarly, the enterprise value to sales ratio is 41.42, reflecting the company's valuation relative to its sales.

VNRX's enterprise value to operating cash flow ratio is -3.84, indicating negative operating cash flow. This means the company is spending more cash than it is generating from its operations. Additionally, the earnings yield of -0.62% further highlights the company's negative earnings situation, which can be a red flag for potential investors.

The debt-to-equity ratio of -0.27 suggests that VNRX has more equity than debt, but the negative value indicates potential financial instability. The current ratio of 0.22 implies liquidity challenges, as it is below the standard threshold of 1. This suggests that the company may struggle to meet its short-term obligations, which could impact its financial health.

• VolitionRx Limited (NYSEAMERICAN:VNRX) is set to release its quarterly earnings on March 31, 2025, with an anticipated earnings per share of -$0.06 and revenue of $545,340.
• The company's price-to-sales ratio stands at 40.30, indicating high investor expectations for future growth despite a negative P/E ratio of -1.59.
• VolitionRx faces potential liquidity challenges, as evidenced by a current ratio of 0.22, signaling difficulties in meeting short-term obligations.

VolitionRx Limited, trading as NYSEAMERICAN:VNRX, is a company focused on developing blood tests for cancer detection. As a player in the biotechnology sector, it faces competition from other firms in the diagnostic and cancer detection space. On March 31, 2025, VNRX will release its quarterly earnings, with Wall Street estimating an earnings per share of -$0.06 and revenue of $545,340.

The company has scheduled a conference call on the same day at 4:30 p.m. U.S. Eastern Time to discuss its financial and operating results for the fourth quarter and the full fiscal year 2024. Key figures such as Cameron Reynolds, the President and CEO, and Terig Hughes, the CFO, will host the call, providing insights into the company's performance and future plans.

Despite a negative price-to-earnings (P/E) ratio of -1.59, VNRX's price-to-sales ratio is about 40.30. This means investors are paying $40.30 for every dollar of sales, indicating high expectations for future growth. The enterprise value to sales ratio is similar at 40.66, reflecting the company's valuation relative to its revenue.

The enterprise value to operating cash flow ratio is approximately -3.77, indicating negative operating cash flow. This suggests that the company is currently spending more cash than it is generating from its operations. Additionally, the earnings yield is about -0.63, further highlighting the company's lack of profitability.

VNRX's debt-to-equity ratio is approximately -0.27, suggesting that the company has more equity than debt, which can be a positive sign for financial stability. However, the current ratio is around 0.22, indicating potential liquidity challenges in meeting short-term obligations. This could be a concern for investors looking at the company's ability to cover its immediate liabilities.

• VolitionRx Limited (NYSEAMERICAN:VNRX) is set to release its quarterly earnings on March 31, 2025, with an anticipated earnings per share of -$0.06 and revenue of $545,340.
• The company's price-to-sales ratio stands at 40.30, indicating high investor expectations for future growth despite a negative P/E ratio of -1.59.
• VolitionRx faces potential liquidity challenges, as evidenced by a current ratio of 0.22, signaling difficulties in meeting short-term obligations.

VolitionRx Limited, trading as NYSEAMERICAN:VNRX, is a company focused on developing blood tests for cancer detection. As a player in the biotechnology sector, it faces competition from other firms in the diagnostic and cancer detection space. On March 31, 2025, VNRX will release its quarterly earnings, with Wall Street estimating an earnings per share of -$0.06 and revenue of $545,340.

The company has scheduled a conference call on the same day at 4:30 p.m. U.S. Eastern Time to discuss its financial and operating results for the fourth quarter and the full fiscal year 2024. Key figures such as Cameron Reynolds, the President and CEO, and Terig Hughes, the CFO, will host the call, providing insights into the company's performance and future plans.

Despite a negative price-to-earnings (P/E) ratio of -1.59, VNRX's price-to-sales ratio is about 40.30. This means investors are paying $40.30 for every dollar of sales, indicating high expectations for future growth. The enterprise value to sales ratio is similar at 40.66, reflecting the company's valuation relative to its revenue.

The enterprise value to operating cash flow ratio is approximately -3.77, indicating negative operating cash flow. This suggests that the company is currently spending more cash than it is generating from its operations. Additionally, the earnings yield is about -0.63, further highlighting the company's lack of profitability.

VNRX's debt-to-equity ratio is approximately -0.27, suggesting that the company has more equity than debt, which can be a positive sign for financial stability. However, the current ratio is around 0.22, indicating potential liquidity challenges in meeting short-term obligations. This could be a concern for investors looking at the company's ability to cover its immediate liabilities.

• VolitionRx Limited (NYSE American: VNRX) is set to release its quarterly earnings with an expected EPS loss of $0.06 and revenue of approximately $545,340.
• The company's Nu.Q® Cancer diagnostics test, capable of detecting 21 types of human cancers, positions VolitionRx as a potential leader in the $20 billion liquid biopsy industry.
• Despite its innovative advancements, VolitionRx faces financial challenges, including a negative P/E ratio of -1.60 and a current ratio of 0.22, indicating potential liquidity issues.

VolitionRx Limited (NYSE American: VNRX) is a multi-national epigenetics company known for its innovative cancer diagnostics. The company is set to release its quarterly earnings on March 24, 2025, with analysts predicting an EPS loss of $0.06 and revenue of approximately $545,340. The earnings report will be released before the market opens.

VolitionRx is making strides in the cancer diagnostics field with its Nu.Q® Cancer diagnostics test. This test can detect 21 types of human cancers with high specificity, as highlighted by PR Newswire. The test's rapid and low-cost nature positions it as a potential game-changer in the $20 billion liquid biopsy industry.

The company has also introduced a new industry primer focusing on lung cancer, emphasizing the Nu.Q® Cancer Test's potential to transform the $4 billion lung cancer market. The test aims to improve diagnosis, treatment, and monitoring, offering a low-cost, easy-to-administer solution that requires only a small blood sample.

VolitionRx is conducting a clinical study at National Taiwan University Hospital to validate its Nu.Q® Lung Cancer Test. This study, involving 500 patients, aims to differentiate between malignant and benign pulmonary nodules. The test has already shown promise in distinguishing nodules found through LDCT screening.

Despite its innovative advancements, VolitionRx faces financial challenges. The company has a negative P/E ratio of -1.60, indicating a lack of profitability. Its price-to-sales ratio of 40.62 and enterprise value to sales ratio of 40.99 suggest a high valuation relative to sales. Additionally, the current ratio of 0.22 may indicate potential liquidity issues.

• VolitionRx Limited (NYSE American: VNRX) is set to release its quarterly earnings with an expected EPS loss of $0.06 and revenue of approximately $545,340.
• The company's Nu.Q® Cancer diagnostics test, capable of detecting 21 types of human cancers, positions VolitionRx as a potential leader in the $20 billion liquid biopsy industry.
• Despite its innovative advancements, VolitionRx faces financial challenges, including a negative P/E ratio of -1.60 and a current ratio of 0.22, indicating potential liquidity issues.

VolitionRx Limited (NYSE American: VNRX) is a multi-national epigenetics company known for its innovative cancer diagnostics. The company is set to release its quarterly earnings on March 24, 2025, with analysts predicting an EPS loss of $0.06 and revenue of approximately $545,340. The earnings report will be released before the market opens.

VolitionRx is making strides in the cancer diagnostics field with its Nu.Q® Cancer diagnostics test. This test can detect 21 types of human cancers with high specificity, as highlighted by PR Newswire. The test's rapid and low-cost nature positions it as a potential game-changer in the $20 billion liquid biopsy industry.

The company has also introduced a new industry primer focusing on lung cancer, emphasizing the Nu.Q® Cancer Test's potential to transform the $4 billion lung cancer market. The test aims to improve diagnosis, treatment, and monitoring, offering a low-cost, easy-to-administer solution that requires only a small blood sample.

VolitionRx is conducting a clinical study at National Taiwan University Hospital to validate its Nu.Q® Lung Cancer Test. This study, involving 500 patients, aims to differentiate between malignant and benign pulmonary nodules. The test has already shown promise in distinguishing nodules found through LDCT screening.

Despite its innovative advancements, VolitionRx faces financial challenges. The company has a negative P/E ratio of -1.60, indicating a lack of profitability. Its price-to-sales ratio of 40.62 and enterprise value to sales ratio of 40.99 suggest a high valuation relative to sales. Additionally, the current ratio of 0.22 may indicate potential liquidity issues.